Sensei Biotherapeutics, Inc. appointed Christopher W. Gerry and Phillip B. Donenberg as new directors to its board, increasing the board size from three to five members effective February 13, 2026. This change in board composition is a key governance event for investors.
Key takeaways
The board of directors increased in size from three members to five members.
Christopher W. Gerry (age 46) was appointed as a new director effective February 13, 2026.
Phillip B. Donenberg (age 65) was appointed as a new director effective February 13, 2026.
Mr. Gerry is the President, Principal Executive Officer and General Counsel of the Company.
Mr. Donenberg will be compensated as a director in accordance with the Company's non-employee director compensation program.
Each new director will enter into the Company's standard form of indemnification agreement.